AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Interferon-induced, double-stranded RNA-activated protein kinase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P19525

UPID:

E2AK2_HUMAN

Alternative names:

Eukaryotic translation initiation factor 2-alpha kinase 2; Interferon-inducible RNA-dependent protein kinase; P1/eIF-2A protein kinase; Protein kinase RNA-activated; Tyrosine-protein kinase EIF2AK2; p68 kinase

Alternative UPACC:

P19525; A8K3P0; D6W584; E9PC80; Q52M43; Q7Z6F6; Q9UIR4

Background:

Interferon-induced, double-stranded RNA-activated protein kinase, also known as EIF2AK2, plays a pivotal role in the innate immune response to viral infection. It phosphorylates EIF2S1/eIF-2-alpha, leading to a shutdown of protein synthesis, which is crucial for combating viral replication. Additionally, EIF2AK2 is involved in various cellular processes including apoptosis, cell proliferation, and differentiation.

Therapeutic significance:

EIF2AK2's involvement in Leukoencephalopathy and Dystonia 33 highlights its potential as a therapeutic target. Understanding the role of EIF2AK2 could open doors to potential therapeutic strategies for these neurological disorders, offering hope for advancements in treatment.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.